Anna Zwolinska has been dismissed from the position of Vice President of the Management Board of the Polish biotechnology company Pharmena. Zwolinska will remain in the company on another position.
Anna Zwolinska has been associated with Pharmena since 2005. Initially, she held the position of a manager in the research and development department. Since 2010 she has been the Sales and Marketing Director. The company’s information does not contain information about the reasons for the appeal.
Pharmena is a Polish biotechnology company. Its activity is focused on conducting clinical research on an innovative anti-atherosclerotic drug, production of innovative dermocosmetics and implementation of an innovative dietary supplement used to meet specific nutritional needs in the prevention of atherosclerosis.